REGN241011C1130000
- 1.50
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Regeneron Pharma Is Maintained at Outperform by RBC Capital
Regeneron Pharmaceuticals Analyst Ratings
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,260 From $1,252, Keeps Outperform Rating
Erste Group Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,220
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,247
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,245
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,245
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,242
Regeneron Pharma Is Maintained at Outperform by RBC Capital
Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Maintains $1200 Price Target
Evercore Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,250
Regeneron Downgraded at Leerink After Amgen's Court Win; Truist Defends
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $1,200 to $1,300
4D Molecular Therapeutics Downgraded at Cantor Following Wet AMD Asset Data
Regeneron Pharmaceuticals Analyst Ratings
Wells Fargo Reiterates Overweight on Regeneron Pharmaceuticals, Maintains $1200 Price Target